58 research outputs found
Fluorescence laparoscopy imaging of pancreatic tumor progression in an orthotopic mouse model
The use of fluorescent proteins to label tumors is revolutionizing cancer research, enabling imaging of both primary and metastatic lesions, which is important for diagnosis, staging, and therapy. This report describes the use of fluorescence laparoscopy to image green fluorescent protein (GFP)-expressing tumors in an orthotopic mouse model of human pancreatic cancer.
The orthotopic mouse model of human pancreatic cancer was established by injecting GFP-expressing MiaPaCa-2 human pancreatic cancer cells into the pancreas of 6-week-old female athymic mice. On postoperative day 14, diagnostic laparoscopy using both white and fluorescent light was performed. A standard laparoscopic system was modified by placing a 480-nm short-pass excitation filter between the light cable and the laparoscope in addition to using a 2-mm-thick emission filter. A camera was used that allowed variable exposure time and gain setting. For mouse laparoscopy, a 3-mm 0° laparoscope was used. The mouse’s abdomen was gently insufflated to 2 mm Hg via a 22-gauge angiocatheter. After laparoscopy, the animals were sacrificed, and the tumors were collected and processed for histologic review. The experiments were performed in triplicate.
Fluorescence laparoscopy enabled rapid imaging of the brightly fluorescent tumor in the pancreatic body. Use of the proper filters enabled simultaneous visualization of the tumor and the surrounding structures with minimal autofluorescence. Fluorescence laparoscopy thus allowed exact localization of the tumor, eliminating the need to switch back and forth between white and fluorescence lighting, under which the background usually is so darkened that it is difficult to maintain spatial orientation.
The use of fluorescence laparoscopy permits the facile, real-time imaging and localization of tumors labeled with fluorescent proteins. The results described in this report should have important clinical potential
Secondary osteosarcoma arising after treatment for childhood hematologic malignancies
Secondary osteosarcoma arising after the treatment of hematologic malignancies other than Hodgkin's lymphoma is rare. We report two cases of secondary osteosarcoma arising after treatment for childhood hematologic malignancies (non-Hodgkin's lymphoma and lymphoblastic leukemia). A 10-year-old boy, at the age of 3, was diagnosed with non-Hodgkin's lymphoma. He received chemotherapy, radiation, and bone-marrow transplantation and then was in complete remission. At 6 years, he complained of increasing pain of the right thigh and was diagnosed with osteoblastic osteosarcoma. A 26-year-old man, at the age of 6, was diagnosed as having acute lymphoblastic leukemia (ALL). He received chemotherapy, radiation, and peripheral blood stem cell transplantation (PBSCT). At 11 years after PBSCT, he visited with the complaint of left lumbar swelling. He was diagnosed with chondroblastic osteosarcoma. In both cases alkaline phosphatase (ALP) had already increased prior to the onset of the symptom. We should rule out secondary osteosarcoma at the abnormal elevation of ALP during clinical follow-up of patients after treatment of childhood hematologic malignancies
Disrupting Circadian Homeostasis of Sympathetic Signaling Promotes Tumor Development in Mice
and why disruption of circadian rhythm may lead to tumorigenesis. oncogenic potential, leading to tumor development in the same organ systems in wild-type and circadian gene-mutant mice. is a clock-controlled physiological function. The central circadian clock paces extracellular mitogenic signals that drive peripheral clock-controlled expression of key cell cycle and tumor suppressor genes to generate a circadian rhythm in cell proliferation. Frequent disruption of circadian rhythm is an important tumor promoting factor
The adhesion molecule CEACAM1 (CD66a, C-CAM, BGP) is specifically expressed by the extravillous intermediate trophoblast
CEACAM1 (CD66a, C-CAM, BGP) is an adhesion molecule of the
carcinoembryonic antigen family which has been shown to be normally
expressed at the apical pole of epithelial cells, including the apical
pole of endometrial surface and glandular epithelia, The purpose of the
present study was to investigate its expression pattern at the
maternal-fetal interface, and thus to determine whether CEACAM1 could be
implicated in the human implantation process, For this purpose, we
performed immuohistochemistry using the 4D1/C2 monoclonal antibody (mAb)
as well as flow cytometry and Western blot on isolated trophoblast
populations, On the maternal side of the maternal-fetal interface,
CEACAM1 was present in epithelial cells of pregnancy endometrium as well
as in small endometrial vessels, whereas it was absent from decidual
cells, On the fetal side, CEACAM1 was strongly expressed by the
extravillous (intermediate) trophoblast at the implantation site, as
well as by extravillous trophoblast cells with invasive phenotype in
primary culture, as shown by now cytometry and Western blot. Expression
was also observed in placental villous core vessels but was absent from
both villous cyto- and syncytiotrophoblasts throughout the pregnancy. We
conclude that, given its specific expression pattern, CEACAM1 can be a
useful marker for extravillous intermediate trophoblast and might be
functionally implicated in mediating trophoblast/endometrial and/or
trophoblast/endothelial interactions during the trophoblastic invasion
of the endometrium
- …